Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-DC Vaccine, Nivolumab, and Chemotherapy in Resected Pancreatic Adenocarcinoma
NCT04627246Phase 1Active, not recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEP-DC in pancreatic adenocarcinoma (PDAC), sponsored by Lausanne University Hospital. Primary endpoints: Number of cases for which vaccine is produced at 3 years and Assessment of adverse events at 3 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
PEP-DC
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04627246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627246.